4-甲氧基-7-甲基-苯并呋喃 | 1026684-72-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 4-甲氧基-7-甲基-苯并呋喃
• 英文名称: 4-Methoxy-7-methyl-benzofuran
• 英文别名: 4-Methoxy-7-methyl-1-benzofuran
• CAS: 1026684-72-9
• 化学式: C₁₀H₁₀O₂
• 分子量: 162.188
• InChiKey: XCBICAXYZPPPSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  22.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-甲氧基-7-甲基-苯并呋喃 在 正丁基锂 、 3-苄基羟乙基甲基噻唑氯化锂 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.25h， 生成 4-[4-(4-Methoxy-7-methyl-benzofuran-2-yl)-4-oxo-butyryl]-benzoic acid methyl ester
  参考文献：
  名称：

  Discovery of Novel and Potent Retinoic Acid Receptor α Agonists:  Syntheses and Evaluation of Benzofuranyl-pyrrole and Benzothiophenyl-pyrrole Derivatives

  摘要：

  In the course of our studies on retinoic acid receptor (RAR) agonists, we have designed and synthesized a series of benzofuran and benzothiophene derivatives. Some of these compounds (1a,b,e,f,j) markedly inhibited LPS-induced B-lymphocyte proliferation and exerted RAR alpha selectivity. One of them, 4-[5-(4,7-dimethylbenzofuran-2-yl)pyrrol-2-yl]benzoic acid (1b), when orally administered significantly inhibited mouse antibody production and delayed type hypersensitivity (DTH) responses from a dose of 0.1 mg/kg.

  DOI：

  10.1021/jm000098s
• 作为产物：
  描述：

  5-甲氧基-2-甲基苯酚 在 PPA 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 3.5h， 生成 4-甲氧基-7-甲基-苯并呋喃
  参考文献：
  名称：

  Discovery of Novel and Potent Retinoic Acid Receptor α Agonists:  Syntheses and Evaluation of Benzofuranyl-pyrrole and Benzothiophenyl-pyrrole Derivatives

  摘要：

  In the course of our studies on retinoic acid receptor (RAR) agonists, we have designed and synthesized a series of benzofuran and benzothiophene derivatives. Some of these compounds (1a,b,e,f,j) markedly inhibited LPS-induced B-lymphocyte proliferation and exerted RAR alpha selectivity. One of them, 4-[5-(4,7-dimethylbenzofuran-2-yl)pyrrol-2-yl]benzoic acid (1b), when orally administered significantly inhibited mouse antibody production and delayed type hypersensitivity (DTH) responses from a dose of 0.1 mg/kg.

  DOI：

  10.1021/jm000098s

文献信息

• [EN] HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE.<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT OU LA PRÉVENTION DE TROUBLES PROVOQUÉS PAR UNE NEUROTRANSMISSION RÉDUITE DE LA SÉROTONINE, DE LA NORÉPINEPHRINE OU DE LA DOPAMINE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2012036253A1

  公开（公告）日：2012-03-22

  A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents -O- or -CH2-; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).

  通用式（1）表示的杂环化合物或其盐：其中m、l和n分别表示1或2的整数；X表示-O-或-CH2-；R1表示氢、较低的烷基基团、羟基较低的烷基基团、保护基或三较低烷氧基较低的烷基基团；R2和R3，相同或不同，各自独立地表示氢或较低的烷基基团；或R2和R3结合形成环-C3-C8烷基基团；R4表示芳香基团或杂环基团，其中芳香基团或杂环基团可能具有一个或多个任意取代基。
• HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE
  申请人：Ito Nobuaki

  公开号：US20130261081A1

  公开（公告）日：2013-10-03

  A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents —O— or —CH 2 —; R 1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R 2 and R 3 , which are the same or different, each independently represent hydrogen or a lower alkyl group; or R 2 and R 3 are bonded to form a cyclo-C3-C8 alkyl group; and R 4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).

  一种由通式（1）表示的杂环化合物或其盐： 其中，m、l和n分别表示1或2的整数；X表示-O-或-CH2-；R1表示氢、低碳基、羟基-低碳基、保护基或三-低硅氧基-低碳基；R2和R3分别独立地表示氢或低碳基；或者R2和R3结合形成环状C3-C8烷基；R4表示芳基或杂环基，其中芳基或杂环基可能具有一个或多个任意取代基。
• Methods of treating anxiety by administering a substituted quinolone
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US11273168B2

  公开（公告）日：2022-03-15

  A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents —O— or —CH2—; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).

  由通式(1)代表的杂环化合物或其盐： 其中 m、l 和 n 分别代表 1 或 2 的整数；X 代表 -O- 或 -CH2-；R1 代表氢、低级烷基、羟基-低级烷基、保护基或三低级烷基硅氧基-低级烷基； R2 和 R3（相同或不同）各自独立地代表氢或低级烷基；或 R2 和 R3 键合形成环-C3-C8 烷基；以及 R4 代表芳香基团或杂环基团，其中芳香基团或杂环基团可具有一个或多个任意取代基。
• HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE.
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：EP2616460B1

  公开（公告）日：2015-10-28
• US9090572B2
  申请人：——

  公开号：US9090572B2

  公开（公告）日：2015-07-28